Coronavirus Update – 9 April 2020
As of 9 April 2020, the European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance will be postponed and will take place from 28 - 30 October 2020.
• Registrants that are able to attend the new dates will automatically have their registration re-assigned to the new dates. If you are not able to attend, we will refund 100% of your registration fee. This also applies to the networking dinner tickets. Please contact us if you need to cancel your participation by 30 April 2020.
• If you have submitted an abstract, your existing abstract submission will remain valid and will be scored at a later stage. Please let us know if you would like to withdraw and re-submit your abstract. The new abstract deadline is 31 July 2020 You will be informed about the outcome no later than two months prior to the start of the meeting.
• If you have booked a hotel with us, your reservation will be automatically transferred to the new dates. If you are unable to attend and wish to cancel your hotel reservation, you can do that free of charge until 28 September 2020.
The European Meeting on HIV & Hepatitis is exploring options to integrate virtual elements into our live programs. We hope that by diversifying the meeting structure, we will be able to welcome more audiences to this meeting who may encounter issues related to travel and/or health concerns. Please stay tuned for future announcements regarding the format of this meeting.
We are available to answer any questions or concerns that you may have about your participation at the European Meeting on HIV & Hepatitis. For more information, please contact Magdalena Pawlowska at firstname.lastname@example.org
To stay updated on developments about this meeting, make sure you are signed up for our newsletter.
We are proud to announce the European Meeting on HIV & Hepatitis: Treatment Strategies & Antiviral Drug Resistance 2020 will be held on 28 - 30 October 2020 in Paris, France.
The premier European platform for clinicians, allied healthcare providers, researchers and clinical virologists to discuss the latest developments in antiviral therapy and for translating them into new treatment strategies to further improve clinical care.
Founded eighteen years ago as the European HIV resistance workshop, the meeting evolved to embrace all aspects of clinical care of people living with HIV in Europe. Particular emphasis is put on optimal treatment strategies, clinical virology, molecular epidemiology and public health aspects of HIV, HBV and HCV infections throughout Europe.
In the last decade the meeting has been able to capture leading clinicians and researchers from the different regions of Europe. As such, this meeting is the only European platform where HIV-treating physicians and clinical virologists get together on an annual basis to present their latest research results and discuss their clinical implications in detail.
We look forward to seeing you in Paris!
On behalf of the Program Committee,